## In th Claims:

Please cancel claims 16 to 19 without prejudice. No other claim changes are being made, but the remaining unchanged claims are listed herein below:

Claims 1 to 9 (previously canceled).

10(previously added). An equilenin derivative of formula I:

## wherein

 $R_1$  denotes a hydrogen atom, a  $C_1$ - $C_5$ -alkyl group, a  $C_1$ - $C_5$ -acyl group or a benzoyl group,

 $R_2$  denotes a hydrogen atom and  $R'_2$  denotes a fluorine atom, a hydroxyl group or a  $C_1$ - $C_5$ -acyloxy group or  $R_2$  and  $R'_2$  together denote an oxo group,

R<sub>3</sub> denotes a hydrogen atom or a methyl group,

 $R_4$  denotes a hydrogen atom and  $R'_4$  denotes a hydroxyl group or a  $C_1$ - $C_{11}$ -acyloxy group or  $R_4$  and  $R'_4$  together denote an oxo group, a methylene group, a halomethylene group or a dihalomethylene group and

R<sub>5</sub> denotes a hydrogen atom or a methyl group.

11(previously added). The equilenin derivative as defined in claim 10, wherein said  $R_5$  is said hydrogen.

12(previously added). An equilenin derivative selected from the group consisting of

14α,15α-methylenestra-1, 3, 5(10),6,8-pentaene-3, 11 $\beta$ ,17 $\beta$ -triol, 11 $\beta$ ,17 $\beta$ -dihydroxy-14α,15α-methylenestra-1, 3, 5(10),6,8-pentaene-3-yl benzoate,

11 $\beta$ ,17 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-3-yl propionate,

3,11 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-17 $\beta$ -yl decanoate,

3,11 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-17-one,

3-methoxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-11 $\alpha$ ,17 $\beta$ -diyl diacetate,

15β-methyl-14α,15α-methylenestra-1, 3, 5(10),6,8-pentaene-3,11β,17β-triol,

11 $\beta$ -fluoro-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-3,17 $\beta$ -diol,

3,17 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-11-one,

3-methoxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-11 $\alpha$ ,17 $\alpha$ -diyl diacetate,

3-methoxy-14 $\alpha$ ,15 $\alpha$ -methylen-11-oxoestra-1, 3, 5(10),6,8-pentaene-17 $\alpha$ -yl acetate,

 $11\beta$ -hydroxy-17,17-difluoromethylene-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-3-yl benzoate and

 $14\alpha,15\alpha$ -methylene-17,17-bis-methyleneestra-1,3,5(10),6,8-pentaene-3,11 $\alpha$ -diol.

13(previously added). A method of making an equilenin derivative of formula I:

## wherein

 $R_1$  denotes a hydrogen atom, a  $C_1$ - $C_5$ -alkyl group, a  $C_1$ - $C_5$ -acyl group or a benzoyl group,

 $R_2$  denotes a hydrogen atom and  $R'_2$  denotes a fluorine atom, a hydroxyl group or a  $C_1$ - $C_5$ -acyloxy group or  $R_2$  and  $R'_2$  together denote an oxo group,

R<sub>3</sub> denotes a hydrogen atom or a methyl group,

 $R_4$  denotes a hydrogen atom and  $R'_4$  denotes a hydroxyl group or a  $C_1$ - $C_{11}$ -acyloxy group or  $R_4$  and  $R'_4$  together denote an oxo group, a methylene group, a halomethylene group or a dihalomethylene group and

R<sub>5</sub> denotes a hydrogen atom or a methyl group; said method comprising the steps of:

a) reacting diphosphorus tetraiodide in the presence of pyridine with a compound to formula II:

to form an intermediate product, and

b) converting the intermediate product to said equilenin derivative of said formula I.

14(previously added). A pharmaceutical composition comprising at least one member selected from the group consisting of pharmaceutically compatible agents and carriers; and at least one equilenin derivative of formula I:

## wherein

 $R_1$  denotes a hydrogen atom, a  $C_1$ - $C_5$ -alkyl group, a  $C_1$ - $C_5$ -acyl group or a benzoyl group,

 $R_2$  denotes a hydrogen atom and  $R'_2$  denotes a fluorine atom, a hydroxyl group or a  $C_1$ - $C_5$ -acyloxy group or  $R_2$  and  $R'_2$  together denote an oxo group,

R<sub>3</sub> denotes a hydrogen atom or a methyl group,

 $R_4$  denotes a hydrogen atom and  $R'_4$  denotes a hydroxyl group or a  $C_1$ - $C_{11}$ -acyloxy group or  $R_4$  and  $R'_4$  together denote an oxo group, a methylene group, a halomethylene group or a dihalomethylene group and

R<sub>5</sub> denotes a hydrogen atom or a methyl group.

15(previously added). A pharmaceutical composition comprising at least one member selected from the group consisting of pharmaceutically compatible agents and carriers; and

at least one equilenin derivative selected from the group consisting of:

14α,15α-methylenestra-1, 3, 5(10),6,8-pentaene-3, 11β,17β-triol, 11β,17β-dihydroxy-14α,15α-methylenestra-1, 3, 5(10),6,8-pentaene-3-yl benzoate,

 $11\beta$ ,  $17\beta$ -dihydroxy- $14\alpha$ ,  $15\alpha$ -methylenestra-1, 3, 5(10), 6, 8-pentaene-3-yl propionate,

3,11 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-17 $\beta$ -yl decanoate,

3,11 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-17-one,

3-methoxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-11 $\alpha$ ,17 $\beta$ -diyl diacetate,

15β-methyl-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-3,11 $\beta$ ,17 $\beta$ -triol,

11 $\beta$ -fluoro-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-3,17 $\beta$ -diol,

3,17 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-11-one,

3-methoxy-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-

 $11\alpha$ ,  $17\alpha$ -diyl diacetate,

3-methoxy-14 $\alpha$ ,15 $\alpha$ -methylen-11-oxoestra-1, 3, 5(10),6,8-pentaene-17 $\alpha$ -yl acetate,

 $11\beta$ -hydroxy-17,17-difluoromethylene-14 $\alpha$ ,15 $\alpha$ -methylenestra-1, 3, 5(10),6,8-pentaene-3-yl benzoate and

 $14\alpha,15\alpha$ -methylene-17,17-bis-methyleneestra-1,3,5(10),6,8-pentaene-3,11 $\alpha$ -diol.

Claims 16 to 19 (canceled).

20(previously added). A cyclopropano steroid of formula II:

wherein

 $R_1$  denotes a hydrogen atom, a  $C_1$ - $C_5$ -alkyl group, a  $C_1$ - $C_5$ -acyl group or a benzoyl group,

 $R_2$  denotes a hydrogen atom and  $R'_2$  denotes a fluorine atom, a hydroxyl group or a  $C_1$ - $C_5$ -acyloxy group or  $R_2$  and  $R'_2$  together denote an oxo group,

R<sub>3</sub> denotes a hydrogen atom or a methyl group,

 $R_4$  denotes a hydrogen atom and  $R'_4$  denotes a hydroxyl group or a  $C_1$ - $C_{11}$ -acyloxy group or  $R_4$  and  $R'_4$  together denote an oxo group, a methylene group, a halomethylene group or a dihalomethylene group and

R₅ denotes a hydrogen atom or a methyl group.

21(previously added). A cyclopropano steroid selected from the group consisting of

11α-hydroxy-3-methoxy-14α,15α-methylene-8α,9α-oxidoestra-1,3,5(10)-trien-17α-yl acetate, 3-methoxy-14α,15α-methylene-8α,9α-oxidoestra-1,3,5(10)-trien-11α,17α-diyl diacetate and 3-methoxy-11α-hydroxy-8α,9α-oxido-14α,15α-methylenestra-1,3,5(10)-trien-17β-yl acetate.